Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.


NDAQ:RGC - Post by User

Post by sungrin1309on Nov 28, 2022 8:21am
44 Views
Post# 35133245

$RGC Defensive Stock to include in your Portfolio

$RGC Defensive Stock to include in your Portfolio$RGC Defensive Stock to include in your Portfolio (HEALTHCARE)

Investors and traders alike has seen stock market and crypto market tanked in the past several months due to multiple black swan events ie. Russian-Ukraine War, Fall of Luna/Terra, US Rate hikes, Surge in oil price, and amongst other things, INFLATION.

During this bear market, majority of stock companies and crypto prices have tank-ed, but there is a company that is currently showing resilience and is on an uptrend.

Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD and ASD, and infectious diseases targeting people’s immune system ie. COVID.

The stock price has seen 300% growth since IPO. The stock price has seen days of being shorted by traders in recent months. We will be monitoring these next few days if the stock price will rally to its previous ATH again.

The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.

[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
<< Previous
Bullboard Posts
Next >>